0001209191-22-008158.txt : 20220209 0001209191-22-008158.hdr.sgml : 20220209 20220209175250 ACCESSION NUMBER: 0001209191-22-008158 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220207 FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jiang Wenbin CENTRAL INDEX KEY: 0001872873 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40632 FILM NUMBER: 22608576 MAIL ADDRESS: STREET 1: C/O CYTEK BIOSCIENCES, INC. STREET 2: 46107 LANDING PARKWAY CITY: FREMONT STATE: CA ZIP: 94538 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytek Biosciences, Inc. CENTRAL INDEX KEY: 0001831915 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 472547526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47215 LAKEVIEW BOULEVARD CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: (877) 922-9835 MAIL ADDRESS: STREET 1: 47215 LAKEVIEW BOULEVARD CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: Cytek BioSciences, Inc. DATE OF NAME CHANGE: 20201110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-07 0 0001831915 Cytek Biosciences, Inc. CTKB 0001872873 Jiang Wenbin C/O CYTEK BIOSCIENCES, INC. 47215 LAKEVIEW BOULEVARD FREMONT CA 94538 1 1 0 0 President and CEO Common Stock 2021-12-04 5 G 0 E 5000 0.00 D 7842710 D Common Stock 2022-02-07 4 S 0 20000 14.40 D 7889375 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 6, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 66,665 shares received as a liquidation distribution from WYTJ LLC. In prior reports, the Reporting Person reported beneficial ownership of 2,666,600 shares of the Issuer's common stock held by WYTJ LLC. /s/ Valerie Barnett, Attorney-in-Fact for Wenbin Jiang 2022-02-09